Home > Cardiology > AHA 2021 > Vascular Diseases: PVD > REDUCE-IT: Cardiovascular risk reduction with icosapent ethyl in PAD

REDUCE-IT: Cardiovascular risk reduction with icosapent ethyl in PAD

Presented By
Dr Deepak Bhatt, Brigham and Women’s Hospital, Boston, USA
Conference
AHA 2021
Trial
Phase 3, REDUCE-IT
Icosapent ethyl was associated with cardiovascular risk reduction in patients with prior peripheral artery disease (PAD) in a post-hoc analysis of the REDUCE-IT trial. A significant 32% reduction in total ischaemic events was demonstrated over approximately 5 years in patients with PAD treated with icosapent ethyl. The results in this subpopulation are consistent with the overall trial results [1]. The randomised, phase 3 REDUCE-IT trial (NCT01492361) was conducted to investigate the safety and efficacy of icosapent ethyl in patients at high risk for cardiovascular events [2]. For the primary analysis, 8,179 patients who were treated with statins were randomised 1:1 to 4 g icosapent ethyl once daily or placebo. After approximately 5 years of follow-up, a relative risk reduction in cardiovascular events of 24.8% was observed in participants receiving icosapent ethyl...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on